The search for a sequencing thoroughbred

Article Abstract:

Connecticut-based 454 Life Sciences announced the commercial launch of the Genome Sequencer 20 (GS20), its innovative and potentially cost-effective sequencing technology in October 2005. The GS20 and a similar technology developed by an academic group led by George Church at Harvard University are at the forefront of a program by the US National Human Genomic Research Institute (NHRGI) that aims to bolster efforts at methods capable of sequencing an entire human genome for US$100,000.

Human genome, 454 Life Sciences

---

A reprise for collaborative financing in biotech

Article Abstract:

Four biotech companies have raised money by a stratagem known as "Collaborative development financing" which allows the companies to retain the value of their drugs by developing them further without going through early licensing. The pros and cons of such a strategy from the viewpoint of benefits accruing for the companies involved in such collaborations are discussed.

---

The investment banker's view

Article Abstract:

A leading investment banker has given his views on the future prospects of the biotechnology industry and also the investment bankers' role in biotechnology industry. The biotech industry should maintain its high level of innovation while adopting an enhanced commercial orientation that drives earnings growth.

Forecasts, trends, outlooks, Financial Planning, Methods, Industry forecasts

Similar abstracts:

• Abstracts: Colombia's Uribe goes for second round. Presidential race takes shape. Bachelet gets off to confident start
• Abstracts: Turning professional. The million pound boy's club. Accountants on top
• Abstracts: Exploring the role of culture in trust development with service providers. Business (not) as usual: crisis management, service recovery and the vulnerability of organisations
• Abstracts: When is a lifting movement too asymmetric to identify low-back loading by 2-D analysis? Scaling of lifting forces in relation to object size in whole body lifting
• Abstracts: First-in-class biologic to enter rheumatoid arthritis fray. Alfimeprase to succeed Genentech's alteplase?

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.